Product Description
Cigna Qingdao is mainly engaged in the intermediates of febuxostatin, ceflothrin, eprazole, flubiprofen, phenalidone, tovaptan, rivaroxaban and Avanafil, terbinafine intermediates, thioacetamide and thiophene and their derivatives.
AI Product Description
*The following content is generated by AI and is for reference only.
C20-OtBu-Glu(OtBu)-AEEA-AEEA-OH is a specialized polyethylene glycol (PEG) analog and amino acid-based linker widely utilized in the synthesis of complex bioconjugates, particularly antibody-drug conjugates (ADCs) and peptide therapeutics. This compound features a robust backbone incorporating two units of 3-amino-1,4-dioxa-8-azacyclodecane (AEEA), which serves as a hydrophilic spacer to enhance solubility and reduce immunogenicity in final drug products. The molecule is strategically protected with tert-butyl groups on the carboxylic acid of glutamic acid (Glu) and the C-terminal amine, ensuring selective reactivity during solid-phase or solution-phase synthesis while preventing unwanted side reactions.
The primary application of this reagent lies in medicinal chemistry for constructing precise linkers that connect cytotoxic payloads to monoclonal antibodies. The AEEA segments provide flexibility and stability, crucial for maintaining the integrity of the ADC in circulation until it reaches the target tumor site. Furthermore, the protected functional groups allow chemists to fine-tune the conjugation process, enabling the attachment of various drugs or fluorophores with high specificity. Its structure supports the development of next-generation therapeutics by improving pharmacokinetic profiles and minimizing off-target toxicity. Researchers utilize this building block to optimize the therapeutic index of novel compounds, making it an essential component in modern pharmaceutical R&D pipelines. The compound is typically supplied in high purity grades suitable for GMP-compliant manufacturing processes, ensuring consistency and safety in clinical trial materials. By facilitating the creation of stable and effective bioconjugates, C20-OtBu-Glu(OtBu)-AEEA-AEEA-OH plays a pivotal role in advancing cancer treatments and other targeted therapies, bridging the gap between chemical synthesis and biological efficacy.